Tema Etfs LLC Acquires 7,927 Shares of Edwards Lifesciences Corporation $EW

Tema Etfs LLC increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 55.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,348 shares of the medical research company’s stock after purchasing an additional 7,927 shares during the quarter. Tema Etfs LLC’s holdings in Edwards Lifesciences were worth $1,738,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of EW. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 1.2% during the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after acquiring an additional 798,801 shares in the last quarter. Geode Capital Management LLC boosted its stake in Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after purchasing an additional 45,555 shares during the period. Jennison Associates LLC boosted its stake in Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. Finally, Ninety One UK Ltd raised its stake in shares of Edwards Lifesciences by 14.0% in the 3rd quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after purchasing an additional 969,030 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EW. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a report on Thursday, December 18th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Finally, UBS Group reissued a “neutral” rating and set a $95.00 price target (up from $92.00) on shares of Edwards Lifesciences in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $94.87.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 over the last quarter. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 2.4%

EW stock opened at $83.07 on Tuesday. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The stock has a market cap of $48.20 billion, a price-to-earnings ratio of 35.80, a price-to-earnings-growth ratio of 3.46 and a beta of 0.95. The company has a fifty day moving average price of $85.06 and a two-hundred day moving average price of $80.42. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company’s revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.